Myriads of cutaneous manifestations with Nilotinib, treated by acitretin – a case report
A remarkable advancement is been made in the treatment of cancer, through chemotherapeutic drugs like tyrosine kinase inhibitors (TKI), etc. Chemotherapy induced cutaneous side effects are multiple and usually they are underreported. Nilotinib is a second generation TKI, which is approved for imatin...
Main Authors: | Amrita A Hongal, T N Revathi, Seetharampura Ramamurthy Radhika, Kanathur Shilpa |
---|---|
Format: | Article |
Language: | English |
Published: |
Wolters Kluwer Medknow Publications
2020-01-01
|
Series: | Indian Journal of Drugs in Dermatology |
Subjects: | |
Online Access: | http://www.ijdd.in/article.asp?issn=2455-3972;year=2020;volume=6;issue=2;spage=85;epage=87;aulast=Hongal |
Similar Items
-
A rare case of hypocalcemia induced by nilotinib
by: Marija Petrić, et al.
Published: (2017-03-01) -
Update on the management of Philadelphia chromosome positive chronic myelogenous leukemia: role of nilotinib
by: Emole J, et al.
Published: (2016-02-01) -
Molecular response in long-term monitoring of patients with chronic myelogenic leukemia (CML) on nilotinib therapy
by: Dragomira Nikolova, et al.
Published: (2021-01-01) -
Acitretin in pediatric dermatoses
by: Manjyot Gautam, et al.
Published: (2016-01-01) -
Economic evaluation of dasatinib in the treatment of chronic myeloid leukemia patients resistant to imatinib in Chile
by: Milva Caputo, et al.
Published: (2011-04-01)